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Abstract— The paper gives a summary of 2014 year results 
in the topic of physiological modeling and control achieved 
by the Physiological Controls Group of the Obuda 
University. The presentation is integrated in the tradition 
established years ago at IEEE INES conferences and 2014’s 
IEEE SACI conference summarizing the latest results 
obtained by the group. Four topics are presented, 
highlighting collaboration with our partner research 
institutes as well: modern robust control of diabetes, 
antiangiogenic model-based tumor control, biostatistical 
modeling methods of diabetes, control of peristaltic pumps 
in hemodialyisis problem. 
I. INTRODUCTION 
In the biomedical research domain, experts typically 
face two major problems: 
1) understanding the physiological behavior of the 
system and transform it into a (mathematical) model; 
2) finding sufficiently accurate methods and 
sensory input modes to detect the required signals. 
The aim of physiological modeling and control – a sub-
discipline of biomedical engineering – is to study, model 
and understand biological processes, then to apply 
identification and control strategies on it as a system [1]. 
This approach enables the automated treatment of various 
diseases (ex. diabetes or cancer) and injuries of the human 
body (e.g. bio-prosthetics) by designing closed-loop 
control systems; hence, enabling personalized healthcare 
by giving the possibility to support medical devices for 
specific diseases or ease everyday life healthcare 
monitoring (i.e. by smartphone applications). Using 
control engineering methodologies (model identification 
and controller design) these protocols could become 
model-based. 
The Physiological Controls Group of the Óbuda 
University performs researches in collaboration with 
together in control applications with the Department of 
Control Engineering and Information Technology of the 
Budapest University of Technology and Economics and 
the Semmelweis University from Budapest in the above 
mentioned topic focusing on four topics: modeling and 
control of diabetes, cancer, peristaltic pumps and 
biostatistical modeling. The current article summarizes the 
newest results obtained following the tradition established 
at previous IEEE INES and SACI conferences [2-5]. 
II. DIABETES MODELING, ESTIMATION AND CONTROL 
Diabetes mellitus is a serious metabolic disease that 
should be artificially regulated. Due to the continuously 
increasing number of diabetic patients, the scientific com-
munity has aimed to improve the treatment of the disease 
by investigating the applicability of an external controller, 
so called artificial pancreas [6] (AP) that focus on Type 1 
Diabetes Models (T1DM) having a general clinical 
symptom, the lack of insulin production of the patients. 
Since T1DM models have usually nonlinear dynamics, 
the controllers used for blood glucose regulation are either 
nonlinear as well, or linear while consider the nonlinearity 
of the model by giving robust guarantees. An example for 
the latter is modern robust (e.g. H∞) control. Robustness is 
necessary, as classical linear control methods (e.g. PID 
control [7]) faces difficulties ensuring the safety of the 
patient, and hence has limited practical use. There are 
several examples for the application of H∞ control in 
blood glucose regulation [8]; however, as a linear control 
methodology. 
A. LMI-based robust LPV control 
We have focused on Linear Parameter Varying (LPV) 
based robust controllers making direct nonlinear control 
possible. Based on the developed robust control 
framework [9] we have investigates the capabilities of a 
robust LPV controller in order to check if it could be 
extended by additional constraints to answer certain 
practical issues, such as avoiding hypoglycemia and high 
carbohydrate intake. 
Based on the model presented in [10] we have 
performed an LPV model synthesis on how to optimize 
scheduling parameter selection and address switching 
control challenges [10]. This investigation focused on 
weighting function determination and Linear Matrix 
Inequalities- (LMI-) based controller design (defining the 
problem as a convex constraint on the sought variables). 
Results were tested on the 6 virtual patients of the 
Cambridge in-silico simulator [6], testing three different 
protocols: 2 days simulation with 150g carbohydrate 
(CHO), 2 days simulation of the protocol based on [11], 2 
days simulation with random meal timing unusually high 
(180g-310g) CHO intake [10]. We have concluded that 
the blood glucose can be maintained in the 
normoglycaemic region (Fig. 1). 
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Figure 1. Simulation results of all LPV type controllers for the second 
meal intake scenario using the control variability grid analysis (CVGA) 
metric of [11]. 
B. Estimation methods for sensor drift compensation 
LPV-based control has proven to be an adequate 
choice, but the time-varying parameters are needed to be 
available for measurement. 
Model-based filters can satisfy the demands of 
estimating the non-observable states. In case of significant 
measurement noise and large unknown disturbances (like 
meal intake, physical activity) Kalman-filtering is usually 
preferred [12]. Extended Kalman Filter (EKF) is used for 
direct nonlinear model estimation, but it may fail if the 
system contains high nonlinearities or initial estimation 
errors. Sigma-point filters have been appeared in order to 
overcome these disadvantages [13]. We have implemented 
different sigma-point filter approaches (Cubature Kalman 
Filter (CKF), Unscented Kalman Filter (UKF), Sparse-
Grid Quadrature Filter (SQKF)) and evaluated them using 
500 simulations lasting 48 hours each, with randomized 
inputs, measurement noise and initial estimation [14]. The 
virtual patients had been taken from the same Cambridge 
in-silico simulator [6]. 
It was demonstrated (Fig. 2) that each investigated 
sigma-point filter proved to be better than the EKF. It was 
also proved that combining with H∞ filtering method 
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Figure 2. Estimation results of standard filters: EKF - solid line, CKF - 
dashed line, UKF - dotted line, SQKF - dash-dotted line. 
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Figure 3. H∞ filtering compared to regular CKF. CKF – solid line,  
UKF - dashed line, SQKF - dotted line, original CKF - dash-dotted line. 
 
the results can even outperform the sigma-point filter 
results (Fig. 3) [14] that gives the possibility of extending 
the robust control framework with robust estimation 
considerations. 
III. BIOSTATISTICAL METHODS FOR GLYCAEMIC 
VARIABILITY INVESTIGATION 
Although T1DM can be treated by exogenous insulin 
intake blood glucose level of the diabetic patients exhibits 
higher-than-normal fluctuations, due to the lack of 
adequate control. It is already recognized that not only too 
low or too high glucose levels give rise to complications, 
but also too high glycemic variability itself [15]. 
The availability of continuous glucose monitoring 
(CGM) devices made it possible to track glycemic 
variability in a practically useful way. CGM systems 
usually have 5 minutes sampling frequency (as opposed to 
self-monitoring) which is sufficient to reconstruct the 
evolution of glucose level over time [16]. 
Even with such measurements available, it is still a 
question of how to define variability. Simple indicators 
such as the standard deviation are typically unable to grab 
to clinically relevant aspects of variability, thus, a myriad 
of more complex indicators were introduced [17]. HbA1c 
(glycolated hemoglobin) is also used in assessing the 
glycemic state of diabetic patients; however, it rather 
describes the average of the blood glucose to which the 
patient is exposed, and not its variability. 
To investigate the connection between HbA1c (and also 
the basic characteristics of the patient: age and duration of 
diabetes) and different metrics quantifying a CGM 
recording, we carried out an empirical investigation taking 
into account 57 children with T1DM treated at the 
Department of Paediatrics of Semmelweis University 
(Budapest, Hungary). The majority of them were 
classified as being poorly controlled as per the guidelines 
of the American Diabetes Association and the 
International Society for Pediatric and Adolescent 
Diabetes. All patients underwent real-time (i.e. non-
blinded) CGM recording. The abovementioned patient 
characteristics and HbA1c levels were extracted from the 
electronic records of the hospital information system [18]. 
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CGM recordings were electronically processed, and the 
following metrics were calculated: 
• Relative time spent in hypo- and hyperglycemia; 
• Mean and median glucose level; 
• Standard deviation and interquartile range of 
glucose level; 
• Mean Amplitude of Glycemic Excursions 
(MAGE). 
These metrics and the patient characteristics – as all 
were continuous variables – were investigated with 
scatterplots and the calculation of correlation coefficients 
among each pair. To account for the possible non-linear 
(or even non-monotone) connections, distance correlation 
was also calculated. 
Age and duration of T1DM showed no clear 
relationship with any descriptor of the glucose levels. 
HbA1c showed clear – and in many cases also statistically 
significant – positive correlation with several indicators of 
glycaemia. It is of particular interest that in several cases, 
the association was not monotone, with a temporary break 
at about 10% HbA1c (Fig. 4). 
The interpretation of this phenomenon is not entirely 
clear; one possible explanation is that due to the poor 
adherence – which was characteristic for most of the 
children in the sample – the subjects temporarily (during 
the CGM measurement) increased their attention to 
glycemic control, which was made possible by the non-
blinded nature of the CGM. This was possible only up to a 
certain point in glycemic state, after which, such 
compensation was no longer that effective. The 
temporarily altered behavior when subjects are aware of 
being monitored is already recognized in many fields of 
medicine, and is called the Hawthorne-effect. The small 
sample size and the convenience sampling of the present 
study limits the robustness of this conclusion, and further 
studies are needed to confirm this finding, and, if 
confirmed, investigate its determinants. 
 
Figure 4. Converting HbA1c to glucose level (“long-term average 
glucose”) and contrasting it with the average calculated from the CGM 
recording (“short-term average”). 
IV. ANTIANGIOGENIC TUMOR GROWTH MODEL 
IDENTIFICATION AND CONTROL 
Our previous researches focused on development of 
control algorithms for antiangiogenic tumor therapy [5], 
[19] for the tumor growth model of [20]. However, based 
on our investigated inhibitors it turned out to identify a 
new tumor growth model. 
The experiment has been done in collaboration with the 
1st Department of Pathology and Experimental Cancer 
Research, Semmelweis University, Budapest, Hungary. 
We have carried out animal experiments to create and 
validate a clinically relevant tumor growth model, 
focusing on the effect of angiogenesis. There were several 
phases; each phase had a specific aim [21]. 
A. C38 colon adenocarcinoma growth identification 
with and without Avastin therapy 
Parametric identification was carried out by fitting a 
curve with two exponential functions. The curve was 
fitted to the average tumor volume of each mouse at the 
measurement points (days). Comparison of the results in 
the three different cases can be found in Fig. 5. The 
coefficients of the exponential functions were positive in 
every case, reflecting the unstability of the system (as it is 
required from a tumor growth model). From the fitted 
curves, transfer function of the models has been 
calculated. From the poles of the systems (third row of 
Fig. 5) we can conclude that each system is unstable. To 
verify the goodness of the created transfer functions, we 
plotted the impulse response of each transfer function 
(second row of Fig. 5), which shows quite similar result to 
the curve fitting (first row of Fig. 5). 
B. Finding the relationship between tumor volume, 
mass and vascularization 
Three attributes of the lethal sized tumor were 
measured: tumor volume, tumor mass and vascularization. 
Relationship between these tumor attributes has been 
investigated with linear regression analysis. To decide 
whether the relationship is significant or not between two 
variables, we used Pearson correlation coefficient (R), 
coefficient of determination (R2) and Analysis of 
Variance (ANOVA) test (level of significance was chosen 
to p = 0.05). We have found that the relationship between 
tumor volume and mass is significant and positive in all 
cases, which means that the larger the volume, the higher 
the mass is. It has been demonstrated vascularization does 
not have significant relationship with volume or mass in 
neither cases. 
C. Finding the effective dosage for optimal therapy 
To compare the results of the three investigated 
experimental cases (Phase I, Phase III/2 control group, 
Phase III/2 case group) we used statistical analysis. Tumor 
volume values measured on the 21st day in each phase 
have been compared. Normality was investigated with 
one-sample Kolmogorov-Smirnov test; it was found that 
each sample has normal distribution (ppI = 0.966, 
ppIII2/control = 0.999, ppIII2/case = 0.608). Homogeneity 
of variance was examined with Levene’s test; the sample 
variances are equal (p = 0:266). 
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Figure 5. Comparison of C38 colon adenocarcinoma growth in three cases. The first row shows the second order exponential curve fitting for the 
average of measurement points; second row is for the impulse response of the identified systems; third row shows poles and zeros of the identified 
systems. 
After confirming normality and homoscedasticity, 
parametric statistical analysis can be used. With Analysis 
of Variance (ANOVA) test more than two samples were 
comparable. ANOVA test was resulted in p = 0.038 value 
meaning that we have to reject the null hypothesis 
according to which there are no differences between the 
means of the samples. To find those samples, which have 
significantly different means, Tukey’s honest significant 
difference (HSD) test was used as post hoc test. The 
results are the following. Phase I and Phase III/2 control 
group are significantly different (p = 0.034), which means 
that Avastin – administered according to the protocol – is 
an effective drug to reduce tumor volume. Phase III/2 
control group and Phase III/2 case group are not 
significantly different (p = 0.416), however Phase I and 
Phase III/2 case group are not significantly different (p = 
0:227) either. This means that the effectiveness of the 
"continuous" (daily) 1/180 dosage (1:11 μg relative to 200 
μg) is comparable with the effectiveness of one large dose. 
V. PERISTALTIC PUMP CONTROL OF HEMODIALYSIS 
MACHINES 
A relevant problem of peristaltic pump is the 
inaccuracy of transfer. The error is resulted by the 
deviation of production, the fatigue of the material and the 
pressure. The inaccurate transfer may cause overdose in 
case of transfer of medical fluids. Furthermore, the 
inaccuracy may cause dehydration or water overdose in 
treated patient, who usually lack the function of the kidney 
(no urine production). In order to provide the necessary 
transfer volumes automatic control should be applied. 
Furthermore, the controller has to be adaptive to react 
effectively on the changing environment, such as the 
changing pressure or the fatigue of material. 
In previous studies [22], [23] a PID controller and a 
fuzzy-system were designed. These control methods were 
compared with a newly designed adaptive neuro-fuzzy 
inference system (ANFIS) [24]. The controllers were 
compared by settling time, overshoot and accuracy. From 
the view of patient the ideal controller is capable to correct 
the errors quickly (short settling time), with no 
unnecessary errors (no overshoot) introduced, and controls 
the system without the accumulation of errors (perfect 
accuracy). By comparing the controllers it was clear that 
the settling time of the examined controllers had only 
minor differences. The classical PID controller operated 
with overshoot, while the soft computing methods 
prevented the overshoot. The accuracy (Table I.) differs 
only slightly in the different controllers. All of the 
mentioned measurements were done with simulation, but 
they were also repeated with the real system. The 
operation of the hemodialysis machine proved the 
simulations are correct. 
TABLE I. ACCURACY MEASUREMENT RESULTS 
Accuracy  
[g * s] 
100 
ml/h 
300  
ml/h 
500  
ml/h 
1000 
ml/h 
1500 
ml/h 
PID -1 -1 1 0 1 
Fuzzy System -3 0 -3 -5 -4 
ANFIS 0 2 -1 -2 -2 
L. Kovács et al. • Physiological Modeling and Control at Obuda University
24
 
Figure 6. Behavior of the real system on the designed modified ANFIS 
controller. 
The presented results confirm that soft-computing 
methods can be effectively used in safety-critical system 
and they have features compared to classical control 
methods capacitate them to apply in practice. 
Furthermore, the ANFIS system has the advantage that it 
is capable to adapt the changing environment. 
VI. CONCLUSIONS 
The paper summarized the latest research results in the 
field of physiological modeling and control carried out by 
Physiological Controls Group of the Obuda University. 
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